Home >> FG-4592 (ASP1517)
Related Products
FG-4592 (ASP1517) HIF prolyl-hydroxylase inhibitor

Catalog No.A4187
Size Price Stock Qty
10mM (in 1mL DMSO)
In stock
Evaluation Sample
In stock
In stock
In stock

Tel: +1-832-696-8203

Email: sales@apexbt.com

Worldwide Distributors


Sample solution is provided at 25 µL, 10mM.

Product Citations

1.Kiriakidis S, Hoer SS, et al. "Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor." Kidney Int. 2017 May 12. pii: S0085-2538(17)30180-1. PMID:28506759

Quality Control

Chemical structure

FG-4592 (ASP1517)

Related Biological Data

FG-4592 (ASP1517)

Biological Activity

Description FG-4592 is an inhibitor of HIF α prolyl hydroxylase.
Targets HIF α prolyl hydroxylase          


Cell experiment [1]:

Cell lines

PC-12 cells

Preparation method

The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20 °C for several months.

Reaction Conditions

5, 20 or 50 μM


FG-4592 showed significant protection effect against the TBHP-induced cell death.

Animal experiment [1]:

Animal models

Mouse model of spinal cord injury

Dosage form

50mg/kg/day; i.p.; for 7 days


In a mouse model of spinal cord injury, FG-4592 administration improved recovery and increased the survival of neurons in spinal cord lesions.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.


[1]. Wu K, Zhou K, Wang Y, Zhou Y, Tian N, Wu Y, Chen D, Zhang D, Wang X, Xu H, Zhang X. Stabilization of HIF-1α by FG-4592 promotes functional recovery and neural protection in experimental spinal cord injury. Brain Res. 2016 Feb 1;1632:19-26.

FG-4592 (ASP1517) Dilution Calculator

Concentration (start)
Volume (start)
Concentration (final)
Volume (final)


FG-4592 (ASP1517) Molarity Calculator



Chemical Properties

Cas No. 808118-40-3 SDF Download SDF
Synonyms N/A
Chemical Name 2-[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid
Canonical SMILES CC1=NC(=C(C2=C1C=C(C=C2)OC3=CC=CC=C3)O)C(=O)NCC(=O)O
Formula C19H16N2O5 M.Wt 352.34
Solubility ≥17.62 mg/mL in DMSO, ≥2.9 mg/mL in EtOH with ultrasonic and warming, <0.94 mg/mL in H2O Storage Store at -20°C
Physical Appearance A solid Shipping Condition Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.


FG-4592 (also known as ASP1517), 2-(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxamido)acetic acid, is a potent small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH), an enzyme up-regulating the expression of endogenous human erythropoietin (Epo). It is currently being investigated as an oral treatment for anemia associated with chronic kidney disease (CKD). Unlike other anemia treating agents, erythropoiesis-stimulating agents (ESAs), FG-4592 inhibits HIF, through a distinctive mechanism, by stabilization of HIF. According to previous studies, FG-4592 is capable of correcting and maintaining hemoglobin levels in CKD patients not receiving dialysis and in patients of end-stage renal disease who receives dialysis but do not need intravenous iron supplement.


1. Luis Borges. Different modalities of erythropoiesis stimulating agents. Port J Nephrol Hypert 2010; 24(2): 137-145
2. “FibroGen and Astellas announce initiation of phase 3 trial of FG-4592/ASP1517 for treatment of anemia of chronic kidney disease” Fibrogen Press Release. Dec 11 2012
3. “FibroGen announces initiation of phase 2b studies of FG-4592, an oral HIF prolyl hydroxylase inhibitor, for treatment of anemia”